TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Problems

Hirsutism

Key Statistics

  • 5–10% — Women of reproductive age affected
  • >70% — Of cases caused by PCOS
  • 0.2% — Cases due to ovarian/adrenal tumour

Don't-miss facts

  1. Post-menopausal woman with new-onset severe hirsutism → TVS mandatory to exclude ovarian hyperthecosis and ovarian tumour; refer urgently if testosterone ≥3 nmol/L

  2. Urgent endocrine referral: testosterone ≥6 nmol/L (pre-menopausal), sudden onset, rapid progression, pelvic/abdominal mass, virilisation (voice, muscle bulk, clitoromegaly)

  3. COC first line if fertility not sought; off-label except Dianette; high VTE risk → EE 20 µg + low-risk progestin

  4. Add antiandrogen only after 6 months of COC monotherapy fails — combination is not standard first line; all antiandrogens feminise a male fetus (contraception mandatory)

  5. Flutamide → hepatotoxicity (liver transplant); CPA → VTE; spironolactone → hyperkalaemia; finasteride only partially effective

  6. Allow 6 months to detect and 9 months for maximal treatment effect — do not switch early

  7. Metformin is no better than placebo for hirsutism; reserve for PCOS + type 2 diabetes failing lifestyle or unable to take COC

  8. NCCAH screening in high-risk women (family history; Ashkenazi Jewish, Hispanic, Eastern European): 17- hydroxyprogesterone in follicular phase (random if irregular/amenorrhoeic)

Ferriman–gallwey cutoffs by ethnicity

UK/US Black or White ≥8 Mediterranean/Hispanic/Middle Eastern ≥9 South American ≥6 Far/SE Asian ≥3

Han Chinese ≥2 Southern Chinese ≥7

Quick recall

5–10% prevalence · PCOS >70% of cases · tumours 0.2% (~50% malignant) · idiopathic hirsutism 5–20% Hair cycle: anagen 2–7 y, catagen 3 wk, telogen 3 mo, exogen 2–5 mo; facial anagen ~4 months Testosterone binding: 70–80% SHBG, 20–30% albumin; bioavailable = free + albumin-bound “Permanent” reduction = ≥30% terminal hair loss sustained beyond one growth cycle (4–12 months) Eflornithine 11.5%: results 6–8 weeks; apply ≥5 min after hair removal; avoid in pregnancy/breastfeeding/<19 years NCCAH prevalence: Ashkenazi Jewish 3.7%, Central European 2%, White 0.1% Pregnancy: theca lutein cysts 10–20% with trophoblastic disease; 30% virilise; luteoma resolves within weeks postpartum

Abbreviation Key

  • PCOS — polycystic ovary syndrome
  • EE — ethinyl estradiol
  • FGS — Ferriman–Gallwey score
  • CPA — cyproterone acetate
  • SHBG — sex hormone-binding globulin
  • ESHRE — European Society of Human Reproduction and Embryology
  • COC — combined oral contraceptive
  • LC–MS/MS — liquid chromatography–tandem mass spectrometry
  • DHEAS — dehydroepiandrosterone sulfate
  • TVS — transvaginal sonography
  • NCCAH — non-classical congenital adrenal hyperplasia
  • VTE — venous thromboembolism
  • OHT — ovarian hyperthecosis
  • HAIR-AN — hyperandrogenism, insulin resistance, acanthosis nigricans
  • GnRHa — gonadotrophin-releasing hormone analogue/agonist
  • hCG — human chorionic gonadotrophin

Source: Sundararajan S et al. Hirsutism: a guide for the obstetrician and gynaecologist. The Obstetrician & Gynaecologist 2025;27:122–134. doi:10.1111/tog.12974

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free